The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell ...
Immunocore is expanding its ImmTAX platform into autoimmune disease, outlining plans to start first‑in‑human trials of ...
Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for the treatment of hematological malignancies, today announced that it has received ...
The growing use of immuno-oncology, advancing bioinformatics analysis, and rising investment in precision medicine are driving the immune repertoire sequencing market.Austin, Texas, Jan. 22, 2026 ...
Statewide Practice Enrolling Patients in Global, Late-Phase Clinical Trial ...
The overall sentiment of these big-money traders is split between 42% bullish and 50%, bearish. Out of all of the options we uncovered, there was 1 put, for a total amount of $27,360, and 13, calls, ...
New immune profiling data confirms disease-modifying mechanism, reinforces earlier signals of fibrosis resolution, lung repair, and improved lung function LA JOLLA, CA, Jan. 08, 2026 (GLOBE NEWSWIRE) ...
CAR031's global reach," including in China, as a potential treatment for liver and other solid tumors, AbelZeta CEO Tony Liu said.
UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...
Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...
Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results